Sage Therapeutics (SAGE) stock soared higher by 37% on the companies phase 2 data release, for the indication of severe Postpartum Depression or PPD. SAGE-547 has a differentiated mechanism of action (moa), and clean safety profile. From their press release today.
"SAGE-547 achieved primary objective with a significant reduction in HAM-D total score compared to placebo at 60 hours (p=0.008). Baseline mean HAM-D scores were severe (28.1 for SAGE-547; 28.8 for Placebo), SAGE-547 showed reduction in HAM-D of greater than 20 points at 60 hours. Improvement was 12 points greater vs. placebo. Improvement maintained through 30-day follow-up (p=0.01)."
Quick Facts:
Shares Out 32M
Market Cap: $1.2b
Cash: 150m
Patent: 2034
These results in PPD, signal the potential for other CNS uses. SAGE-547 works very rapidly, and maintained the results through the 30 day follow-up period. Thank you for reading.
"SAGE-547 achieved primary objective with a significant reduction in HAM-D total score compared to placebo at 60 hours (p=0.008). Baseline mean HAM-D scores were severe (28.1 for SAGE-547; 28.8 for Placebo), SAGE-547 showed reduction in HAM-D of greater than 20 points at 60 hours. Improvement was 12 points greater vs. placebo. Improvement maintained through 30-day follow-up (p=0.01)."
Quick Facts:
Shares Out 32M
Market Cap: $1.2b
Cash: 150m
Patent: 2034
These results in PPD, signal the potential for other CNS uses. SAGE-547 works very rapidly, and maintained the results through the 30 day follow-up period. Thank you for reading.
No comments:
Post a Comment